Skip to main content
. 2017 Nov 13;18:536. doi: 10.1186/s13063-017-2234-7

Fig. 1.

Fig. 1

Study design. aNot more than 48 h may elapse between confirmation of moderate or severe acute respiratory distress syndrome (ARDS) during screening and administration of the first dose of study drug on day 1. Once eligibility has been met, randomization can occur during screening or pre-dose on day 1